Abstract Phosphatase of regenerating liver (PRL)-3, encoding a 22-kD low molecular weight tyrosine phosphatase, has been reported to be associated with metastasis of colorectal carcinoma. We assessed the levels of PRL-3 mRNA expression to know whether its up-regulation was involved in progression and metastasis of gastric carcinoma. Levels of PRL-3 expression in 94 human gastric adenocarcinomas and 54 matched lymph node metastases were detected by in situ hybridization and compared with clinicopathological characteristics including prognosis. High PRL-3 expression was detected in 36.2% of primary gastric carcinoma (with nodal metastasis, 55.6%; without nodal metastasis, 10%; P<0.001) and in 74.1% of lymph node metastases. The incidence of high PRL-3 expression in lymph node metastasis was significantly higher than in primary tumors (P<0.044). Moreover, high expression of PRL-3 was closely associated with tumor size, lymphatic invasion, venous invasion, extent of lymph node metastasis, and tumor stage. These results suggest that high PRL-3 expression may participate in the progression and metastasis of gastric carcinoma. PRL-3 might be a novel molecular marker for aggressive gastric cancer.
Introduction
Gastric cancer incidence and mortality has fallen dramatically over the last 50 years in many regions, but remains the second most common cancer worldwide [1, 23] . Metastasis of gastric cancer to the lymph nodes, peritoneum, and/or other organs is often responsible for highest mortality rate because the primary tumors can usually be surgically removed [4, 9] . Involvement of regional lymph nodes is an important prognostic factor for gastric carcinoma, i.e., if lymph nodes are found to be negative for metastasis by thorough pathologic examination, more than 50% of the patients may be expected to survive for 5 years; otherwise, the survival rate drops to less than 10% [4, 8] . Mechanisms of gastric cancer metastasis are not fully clarified because of the involvement of multiple steps with the accumulation of altered expression of a number of different genes [29] . Although many molecular factors participating in metastasis have been identified from studies that use microarray expression profiling [9] , much remains to be learned about the process to provide a new therapeutic target for these metastatic lesions.
Protein tyrosine phosphatases (PTPs) play fundamental roles in regulating diverse proteins that participate essentially in every aspect of cellular physiological and pathogenic processes [33] . Phosphatase of regenerating liver (PRL)-1, PRL-2, and PRL-3 represents a novel class of PTPs superfamily members in possessing a unique COOHterminal prenylation motif with PTP active site signature sequence CX 5 R [5, 30] . PRL phosphatases were found to be associated with the early endosome and plasma membrane in their prenylated state, while nuclear localization of these enzymes may occur in the absence of prenylation [31] . All are proteins of about 20-kD and share 75% amino acid sequence similarity [6, 30] . PRL-1 was originally identified as an immediate early gene whose expression was induced in mitogen-stimulated cells and regenerating liver [16] . Overexpression of PRL-1 and PRL-2 transformed mouse fibroblasts and hamster pancreatic epithelial cells in culture and promoted tumor growth in nude mice, suggesting that it may participate in the tumorigenesis [5, 6] .
PRL-3 has been found to enhance growth of human embryonic kidney fibroblasts [14] . Among normal human adult tissues, it is expressed predominantly in the heart and skeletal muscle cells with lower expression in the pancreas, and this expression pattern is distinct from the wider expression of PRL-1 and PRL-2 [14] . Gene expression profiling using serial analysis of gene expression (SAGE) revealed that among 144 up-regulated genes detected in liver samples of metastatic colorectal cancer, PRL-3 was the only gene consistently overexpressed in all cancer metastasis cases examined with lower levels in non-metastatic tumors and normal colorectal epithelium [24] . Overexpression of PRL-3 was reported to be associated with human colorectal cancer metastasis and PRL-3 was apparently expressed in colorectal cancer metastases to any organ [2, 11] . In addition, stable transfection of wild-type PRL-3 in non-or less metastatic CHO or mouse melanoma B16 cells has been reported to induce the acquisition of metastasis-associated phenotypes and to confer metastatic ability, whereas a catalytically inactive PRL-3 mutant greatly reduced the effect on promoting cell migration [28, 32] . Moreover, specific anti-sense oligodeoxynucleotide and phosphatase inhibitors could reverse the acquired higher migratory ability with exogenously overexpressed PRL-3 [28] .
Conversely, transient down-regulation of PRL-3 expression in DLD-1 human colon cancer cells with a specific small interfering RNA-abrogated cellular motility in vitro and in vivo hepatic colonization after infection into the nude mice spleen, suggesting the possible contribution of PRL-3 to the establishment of liver metastasis, especially at the step in which cancer cells leave the circulation to extravasate into the liver tissue [11] . Moreover, stable knockdown of PRL-3 by artificial microRNA in SGC7901 human gastric cancer cells effectively suppressed the growth of experimental peritoneal metastases in nude mice independent of cellular proliferation [13] . These experimental evidences support the significant role of overexpressed and catalytically active PRL-3 in cancer metastasis.
We previously conducted an immunohistochemical analysis of human gastric carcinomas using anti-PRL-3 antibody and reported that high expression of PRL-3 immunoreactivity was frequently detected in those with lymph node metastasis [15] . However, we could not eliminate the possibility of cross-reaction of the antibody to PRL-1 and/or PRL-2. To clarify this, in the present study, we investigated the levels of PRL-3 mRNA expression by highly specific in situ hybridization (ISH) in the primary gastric carcinoma tissues and corresponding non-neoplastic mucosa and matched regional lymph node metastases and correlated with clinicopathological features and prognosis of the patients.
Materials and methods

Tissue samples
A total of 152 formalin-fixed and paraffin-embedded surgical specimens of primary human gastric carcinomas and lymph node metastases were collected from the Department of Pathology, Kobe University Hospital. They consisted of 54 cases of primary tumors along with matched lymph node metastases and 40 cases of primary tumors without lymph node metastasis. Four cases with liver metastasis and peritoneal metastasis were also available. They consisted of 68 men and 26 women with an age range of 34-87 years and mean of 66.82 years. Informed consent was obtained from all patients. We classified gastric carcinomas according to the criteria of the Japanese Classification of Gastric Carcinoma [10] .
Oligonucleotide probe and ISH
The expression levels of PRL-3 in tissue sections were analyzed using ISH as described elsewhere with some modifications [3, 11] . Specific antisense oligonucleotide DNA probe was designed complementary to the mRNA transcript of PRL-3 gene, based on published reports of the cDNA sequences. The sequence of probe was 5′ GTTGATGGCTCCGCGGCG-Brigati Tail-3′ with 72.2% GC content. The specificity of the oligonucleotide sequences was initially determined by a GenBank/European Molecular Biology Laboratory database search using the Genetics Computer Group sequence analysis program (Genetics Computer Group, Madison, WI, USA) based on the FastA algorithm [18] that showed 100% homology with the target gene and minimal homology with nonspecific mammalian gene sequences. DNA probe was synthesized with six biotin molecules (hyperbiotinylated) at the 3′ end via direct coupling using standard phosphormidine chemistry (Invitrogen, Carlsbad, CA, USA) [17] .
ISH was carried out using the Microprobe manual staining system (Fisher Scientific, Pittsburgh, PA, USA). Tissue sections (4 μm) of formalin-fixed, paraffin-embed-ded specimens were mounted on Silane-coated ProbeOn slides (Fisher Scientific). The slides were placed in the Microprobe slide holder, dewaxed, dehydrated, and followed by enzymatic digestion with pepsin (Dako, Carpinteria, CA, USA). Hybridization of the probe was carried out for 90 min at 45°C, and the samples were then washed three times with 2x SSC for 2 min at 45°C. The samples were incubated for 30 min in alkaline phosphatase-labeled avidin (Biomeda, Foster City, CA, USA) at 45°C, briefly rinsed in 50 mM Tris-HCl (pH 7.6), rinsed for 1 min with alkaline phosphatase enhancer, and incubated for 20 min with the chromogen substrate FastRed (Biomeda) at 45°C. Hybridization of the samples with a biotinylated poly(dT) 20 oligonucleotide was used to verify the integrity of mRNA in each sample.
To analyze the specificity of the hybridization signal, we performed the following controls: (1) RNase pretreatment of tissue sections, (2) competitive assay with sense probe, (3) treatment of the samples in the absence of the biotinylated probe to control endogenous alkaline phosphatase, and (4) use of chromogen in the absence of any oligonucleotide probes. A markedly decreased or absent signal was obtained under all of these conditions. For evaluation of staining, normal gastric epithelium, smooth muscle cells of the vessels and infiltrated inflammatory cells were used as internal controls. Staining in more than 25% cancer cells obviously exceeding the internal controls was regarded as "high expression" and negative or no increase of staining in cancer cells compared with them was judged as "low/none expression." The grades of PRL-3 expression were determined by three independent observers (U.A.M., S.S., H.K.) unaware of the clinical and histological diagnoses. All of the sections were scored twice to confirm the reproducibility of the results and any discordant result was settled by using a conference microscope.
Immunohistochemistry
We determined Ki-67 labeling index and apoptotic body index immunohistochemically as described elsewhere [25] , using monoclonal antibody against Ki-67 antigen (Dako, Japan; 1:100 dilution) and polyclonal antibody against single-stranded DNA (ssDNA, Dako; 1:100 dilution), respectively. The Ki-67 labeling index and apoptotic body index were calculated by counting the number of positive cells (%) in a total of 1,000 or more tumor cells observed in ten representative high-power fields. Values were presented as the mean ± SD (standard deviation).
Statistical methods
The relationships between the results of the ISH study and clinicopathological variables were tested by χ 2 test and Mann-Whitney U test. Survival analysis was computed by the Kaplan-Meier method and compared by log-rank test. A P value less than 0.05 was regarded as statistically significant.
Results
We examined the expression and localization of PRL-3 in 148 cases of gastric carcinoma and lymph node metastasis by using ISH method that facilitated the study of paraffinembedded specimens. We confirmed that all samples had intense histochemical reaction with poly(dT) 20 probe, indicating that the mRNA was well preserved (Fig. 1a-c) .
Negative to weak PRL-3 expression was detected in nonneoplastic gastric mucosa including foveolar epithelia, fundic and pyloric glandular cells. Weak to moderate expression was also detected in smooth muscle cells of the vessels and in some inflammatory cells, such us lymphocytes and plasma cells. However, in the tumor cells, PRL-3 expression was varied and observed heterogeneously among the cases. Prominent hybridization indicating high PRL-3 expression was detected in 34 (36.2%) of 94 primary gastric carcinoma cases examined.
Representative results of PRL-3 ISH staining are shown in Fig. 1d-i . We then analyzed the relationship between expression of PRL-3 and clinicopathological parameters of gastric carcinoma. Results are summarized in Table 1 . High expression of PRL-3 was significantly associated with gender (P=0.010), tumor size (P=0.017) and stage of tumor (P=0.008). Also, a similar correlation was observed with cancer progression, such as lymphatic invasion (P< 0.001), venous invasion (P=0.012) and extent of lymph node metastasis (P< 0.001). Although not statistically significant, the incidence of PRL-3 expression tended to be associated with depth of tumor invasion (P=0.051). Additionally, high expression of PRL-3 was also associated with the high level of Ki-67 labeling index (P=0.032) and low level of apoptotic bodies (P=0.030). There was no significant correlation between PRL-3 expression and age or histological type.
As shown in Table 2 , among primary gastric carcinomas, the incidence of cases with high PRL-3 expression was significantly frequent in carcinomas with nodal metastasis (30 [55.6%] of 54 cases) than in those without nodal metastasis (4 [10%] of 40 cases; (P<0.001). Simultaneously, we also investigated the expression of PRL-3 in regional lymph node metastases. Interestingly, out of 54 cases with lymph node metastases, high PRL-3 expression was detected in 40 cases (74.1%). The frequency of high PRL-3 expression was increased in matched lymph node metastases in comparison with primary gastric carcinomas (P=0.044). Moreover, high PRL-3 expression was also detected in other metastatic sites, such as liver and peritoneum.
Finally, we checked the survival rate of gastric cancer patients after surgery. The cases with high expression of PRL-3 showed a tendency to have a worse prognosis than the cases with low/none expression of PRL-3, although it was not statistically significant (P=0.165) (Fig. 2) .
Discussion
Histochemical evaluation of PRL-3 expression in human cancer tissues has been reported mainly on colorectal carcinomas. Bardelli et al. developed ISH methods for the study of paraffin-embedded colorectal cancer sections and reported that PRL-3 expression was elevated in nearly all metastatic lesions derived from colorectal cancers, regardless of the site of metastasis, while they observed little or no PRL-3 mRNA expression in normal colon, non-metastatic primary cancers, or metastatic lesions derived from cancers of pancreas, stomach or esophagus [2] . On the other hand, Kato et al., also using ISH methods on paraffin-embedded specimens, detected PRL-3 expression in primary colorectal cancers of which the frequency of up-regulated PRL-3 expressions in cases with liver or lung metastasis was statistically higher than that in cases without either type of metastasis [11] . Peng et al. prepared a specific monoclonal antibody against human PRL-3 and detected its immunoreactivity in 7% of normal colorectal epithelia, 23.9% of primary colorectal cancers, 53.7% of metastatic lymph nodes, and 66.7% of liver metastases [19, 20] . The levels of PRL-3 expression were determined by ISH. Grades of PRL-3 staining were classified as high, low, or negative as described in the text. b According to the criteria of the Japanese Classification of Gastric Carcinoma [10] . Well, well-differentiated type including papillary adenocarcinoma, well-differentiated tubular adenocarcinoma and moderately differentiated tubular adenocarcinoma; poorly, poorly differentiated type including solid-type poorly differentiated adenocarcinoma, non-solid type poorly differentiated adenocarcinoma, signet-ring cell carcinoma, and mucinous adenocarcinoma. Depth of carcinoma invasion and extent of lymph node metastasis were classified into T1-T4 and N0-N3, respectively. c Tumor size was divided into two groups according to the maximum diameter. d Statistical analyses were performed by χ 2 test and Mann-Whitney U test. A P value less than 0.05 was regarded as statistically significant. *P<0.05, **P<0.001. e Ki-67 labeling index and apoptotic body index were determined by counting the number of positive cells (%) in a total of 1,000 or more tumor cells observed in ten representative high-power fields (×400). SD Standard deviation Previously, we conducted immunohistochemical analysis of PRL-3 on human gastric cancer tissues using commercial antibody and reported that overexpression of PRL-3 immunoreactivity in primary gastric carcinoma was closely associated with lymphatic invasion, extent of lymph node metastasis and tumor stage [15] . However, as PRL-3 shares 78% and 75% amino acid sequence similarity with PRL-1 and PRL-2, respectively [12] , we could not exclude the possibility of the cross-reaction of the anti-PRL-3 antibody used in the previous study to other PRL family phosphatases.
The present ISH study, highly specific for the detection of PRL-3 mRNA, on the same gastric cancer specimens as was investigated in the previous immunohistochemical analysis [15] confirmed the PRL-3 expression in primary as well as metastatic gastric cancer cells. Interestingly, a high level of PRL-3 expression in primary gastric carcinoma tissue was closely associated not only with clinicopathological factors characterized by immunohistochemistry (i.e., lymphatic invasion, extent of lymph node metastasis, and tumor stage) [15] , but also with tumor size, venous invasion, and either higher levels of Ki-67 labeling index as well as lower levels of apoptotic body index. Moreover, high expression of PRL-3 was significantly frequent in primary gastric carcinoma with nodal metastasis than those without nodal metastasis that was also observed in the previous study [15] . Consistent with the elevated expression of PRL-3 in colorectal cancer metastasis [2, 11, 20, 24] , the frequency of high PRL-3 expression was significantly increased in matched lymph node metastases than in primary gastric tumors.
The growth-promoting effect of ectopically overexpressed PRL-3 in HEK293 human embryonic kidney epithelial cells [14] and mouse B16 melanoma cells [28] have been reported. Although enhanced cell cycle progression and down-regulation of p21 cip1/waf1 , a cyclin-dependent kinase inhibitor, by PRL-1 or PRL-2 typrosine phosphatases, was demonstrated in D27 hamster pancreatic ductal epithelial cells [27] , effect of overexpressed PRL-3 on the cell cycle or apoptosis has not been elucidated yet. These findings suggest that high PRL-3 expression might not only have important roles in invasion and metastasis, but also play some role in cellular proliferation and/or growth of human gastric cancer.
Elevated PRL-3 protein or mRNA expression in the primary tumor has been reported to associate with prognosis, including disease-free-and overall-survival, of colorectal and breast cancer patients [11, 20, 22, 26] . The present study demonstrated that patients with high expression of PRL-3 in their primary gastric cancer tissue tended to have worse prognosis than those with low or negative PRL-3 expression, while we could not obtain a significant statistical difference.
These results overall suggest that overexpression of PRL-3 may contribute to the progression and metastasis of human gastric carcinoma. Histochemical detection of PRL-3 expression may serve as a good marker for the prediction of grade of malignancy. Inhibition of prenylation and/or inactivating the catalytic function of PRL-3 phosphatase could block or reduce the cellular properties of invasion and metastasis [32] . Therefore, elucidation of precise biological function of PRL-3 may provide an attractive molecular target for gastric cancer control. Although it has been reported that PRL-3 interacted with integrin α1 [21] and regulated Rho family GTPases [7] , further investigations will be required to clarify the exact pathway(s) of PRL-3-driven cancer metastasis.
